CA2591413A1 — Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
Assigned to Vertex Pharmaceuticals Inc · Expires 2006-06-22 · 20y expired
What this patent protects
This invention describes compounds of Formula (I), or a pharmaceutically accepted salt thereof, wherein each R3 and R4 is independently H, halogen or C1-4aliphatic optionally substituted with halogen, C1-2aliphatic, OCH3, NO2, NH2, CN, NHCH3, SCH3, or N(CH)2. R2 is a 3-8membered …
USPTO Abstract
This invention describes compounds of Formula (I), or a pharmaceutically accepted salt thereof, wherein each R3 and R4 is independently H, halogen or C1-4aliphatic optionally substituted with halogen, C1-2aliphatic, OCH3, NO2, NH2, CN, NHCH3, SCH3, or N(CH)2. R2 is a 3-8membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R2 is optionally substituted with JR; each X1 and X2 is independently -C(O)-, -NR-, or -SO2- wherein one of X1 or X2 is -NR- and other of X1 or X2 is -C(O)- or -SO2-; R1 and R are as described herein; These compounds are effective as inhibitors of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk) protein kinases. These compounds and pharmaceutically acceptable compositions thereof are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunologically-mediated disease.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.